CA2358508A1 - Therapeutic applications of flint polypeptides - Google Patents
Therapeutic applications of flint polypeptides Download PDFInfo
- Publication number
- CA2358508A1 CA2358508A1 CA002358508A CA2358508A CA2358508A1 CA 2358508 A1 CA2358508 A1 CA 2358508A1 CA 002358508 A CA002358508 A CA 002358508A CA 2358508 A CA2358508 A CA 2358508A CA 2358508 A1 CA2358508 A1 CA 2358508A1
- Authority
- CA
- Canada
- Prior art keywords
- mflint
- cells
- arg
- flint
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11340798P | 1998-12-22 | 1998-12-22 | |
US60/113,407 | 1998-12-22 | ||
USPCT/US99/06797 | 1999-03-30 | ||
PCT/US1999/006797 WO1999050413A2 (en) | 1998-03-30 | 1999-03-30 | THERAPEUTIC APPLICATIONS OF MATURE FLINT (mFLINT) POLYPEPTIDES OR OPG3, A MEMBER OF THE TNF RECEPTOR SUPERFAMILY |
US17223999P | 1999-10-20 | 1999-10-20 | |
US60/172,239 | 1999-10-20 | ||
PCT/US1999/030734 WO2000037094A2 (en) | 1998-12-22 | 1999-12-21 | Therapeutic applications of flint polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2358508A1 true CA2358508A1 (en) | 2000-06-29 |
Family
ID=27378725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002358508A Abandoned CA2358508A1 (en) | 1998-12-22 | 1999-12-21 | Therapeutic applications of flint polypeptides |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1140138A2 (ja) |
JP (1) | JP2003520761A (ja) |
AU (1) | AU2211100A (ja) |
CA (1) | CA2358508A1 (ja) |
WO (1) | WO2000037094A2 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000070174A (ko) | 1997-01-14 | 2000-11-25 | 벤슨 로버트 에이치. | 종양 괴사 인자 수용체 6α 및 6β |
US7285267B2 (en) | 1997-01-14 | 2007-10-23 | Human Genome Sciences, Inc. | Tumor necrosis factor receptors 6α & 6β |
AU2001280460A1 (en) * | 2000-08-02 | 2002-02-13 | Eli Lilly And Company | Pulmonary administration of flint |
GB202016058D0 (en) * | 2020-10-09 | 2020-11-25 | Ucl Business Ltd | Therapeautic treatment |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000070174A (ko) * | 1997-01-14 | 2000-11-25 | 벤슨 로버트 에이치. | 종양 괴사 인자 수용체 6α 및 6β |
US5885800A (en) * | 1997-02-04 | 1999-03-23 | Smithkline Beecham Corporation | DNA encoding tumor necrosis related receptor, TR4 |
WO1999004001A1 (en) * | 1997-07-21 | 1999-01-28 | Zymogenetics, Inc. | Tumor necrosis factor receptor ztnfr-5 |
CA2299619A1 (en) * | 1997-08-06 | 1999-02-18 | Regeneron Pharmaceuticals, Inc. | Human orphan receptor ntr-1 |
AU762959B2 (en) * | 1997-09-18 | 2003-07-10 | Genentech Inc. | DcR3 polypeptide, A TNFR homolog |
WO1999026977A1 (en) * | 1997-11-24 | 1999-06-03 | Biogen, Inc. | Novel receptors opg-2 |
KR20010042364A (ko) * | 1998-03-30 | 2001-05-25 | 피터 지. 스트링거 | 성숙 FLINT(mFLINT) 폴리펩타이드 또는 TNF수용체인 OPG3의 치료학적 용도 |
-
1999
- 1999-12-21 EP EP99966602A patent/EP1140138A2/en not_active Withdrawn
- 1999-12-21 CA CA002358508A patent/CA2358508A1/en not_active Abandoned
- 1999-12-21 WO PCT/US1999/030734 patent/WO2000037094A2/en not_active Application Discontinuation
- 1999-12-21 JP JP2000589204A patent/JP2003520761A/ja not_active Withdrawn
- 1999-12-21 AU AU22111/00A patent/AU2211100A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2211100A (en) | 2000-07-12 |
WO2000037094A2 (en) | 2000-06-29 |
JP2003520761A (ja) | 2003-07-08 |
EP1140138A2 (en) | 2001-10-10 |
WO2000037094A3 (en) | 2000-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040167074A1 (en) | Therapeutic applications of mFLINT polypeptides | |
Brines et al. | Erythropoietin‐mediated tissue protection: reducing collateral damage from the primary injury response | |
EP0885299B1 (en) | Ob receptor and ligands | |
JP4411330B2 (ja) | 腫瘍壊死因子関連リガンド | |
EP1326974B1 (en) | Methods of using a human il-17-related polypeptide to treat disease | |
JP3750819B2 (ja) | C−kit受容体に対するリガンド及びその使用法 | |
WO1997047321A1 (en) | Use of chimeric vaccinia virus complement control proteins to inhibit complement | |
US6475781B1 (en) | Trans-dominant suppressor genes for oligomeric proteins | |
JP2005506287A5 (ja) | ||
CA2181566C (en) | Compositions and methods using unbound mpl receptor for stimulating platelet production | |
JP2005506287A (ja) | 造血障害を治療するためのlp82の使用 | |
US20020069422A1 (en) | New polypeptides and peptides, nucleic acids coding for them, and their use in the field of tumor therapy, inflammation or immunology | |
CA2358508A1 (en) | Therapeutic applications of flint polypeptides | |
US6207454B1 (en) | Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide | |
US7537932B1 (en) | Antibodies that bind purified mammalian FLT3 ligands | |
EP0977859B1 (en) | The neurotrophic factor nnt-1 | |
ZA200005157B (en) | Therapeutic applications of mature flint (mFLINT) polypeptides or OPG3, a member of the TNF receptor superfamily. | |
US20040236088A1 (en) | Novel polypeptide analogs and fusions and their methods of use | |
MXPA00009523A (en) | THERAPEUTIC APPLICATIONS OF MATURE FLINT (mFLINT) POLYPEPTIDES OR OPG3, A MEMBER OF THE TNF RECEPTOR SUPERFAMILY | |
EP1225908A2 (en) | Therapeutic applications of flint polypeptides | |
RU2258710C2 (ru) | Новый цитокин zalpha11-лиганд | |
US20040072745A1 (en) | Therapeutic methods of use for lp229 | |
KR100409099B1 (ko) | 신경 손상 치료 기구 | |
WO1998055141A9 (en) | Methods and products for inducing apoptosis in neuroendocrine cells with macrophage stimulating protein | |
WO2003065981A2 (en) | Therapeutic use for lp229, in particular for wound healing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |